FOX-2 Dependent Splicing of Ataxin-2 Transcript Is Affected by Ataxin-1 Overexpression by Welzel, Franziska et al.
FOX-2 Dependent Splicing of Ataxin-2 Transcript Is
Affected by Ataxin-1 Overexpression
Franziska Welzel
1,3, Christian Kaehler
1,3, Melanie Isau
2,3, Linda Hallen
1, Hans Lehrach
2,
Sylvia Krobitsch
1*
1Otto Warburg Laboratory, Max Planck Institute for Molecular Genetics, Berlin, Germany, 2Department of Vertebrate Genomics, Max Planck Institute for Molecular
Genetics, Berlin, Germany, 3Department of Biology, Chemistry and Pharmacy, Free University Berlin, Berlin, Germany
Abstract
Alternative splicing is a fundamental posttranscriptional mechanism for controlling gene expression, and splicing defects
have been linked to various human disorders. The splicing factor FOX-2 is part of a main protein interaction hub in a network
related to human inherited ataxias, however, its impact remains to be elucidated. Here, we focused on the reported
interaction between FOX-2 and ataxin-1, the disease-causing protein in spinocerebellar ataxia type 1. In this line, we further
evaluated this interaction by yeast-2-hybrid analyses and co-immunoprecipitation experiments in mammalian cells.
Interestingly, we discovered that FOX-2 localization and splicing activity is affected in the presence of nuclear ataxin-1
inclusions. Moreover, we observed that FOX-2 directly interacts with ataxin-2, a protein modulating spinocerebellar ataxia
type 1 pathogenesis. Finally, we provide evidence that splicing of pre-mRNA of ataxin-2 depends on FOX-2 activity, since
reduction of FOX-2 levels led to increased skipping of exon 18 in ataxin-2 transcripts. Most striking, we observed that ataxin-
1 overexpression has an effect on this splicing event as well. Thus, our results demonstrate that FOX-2 is involved in splicing
of ataxin-2 transcripts and that this splicing event is altered by overexpression of ataxin-1.
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Introduction
Alternative splicing is a key posttranscriptional mechanism
controlling the expression of numerous gene products contributing
to proteome diversity in a cell- and tissue-specific manner [1,2,3].
Variations in the intracellular concentration and localization of
splicing factors influence alternative splicing and may be a natural
mechanism for regulating gene expression [4]. Aberrant splicing
perturbs this normal balanced functionality and is related to
a number of human disorders causing disease directly or mediating
disease modification and susceptibility, as disease genes have the
propensity to be more intron-rich, and therefore are more
susceptible to splicing deregulation [1,3,5].
Of note, a large group of RNA binding proteins regulating pre-
mRNA splicing have been identified, but for most the precise
splicing events are barely understood. To a certain extent the
splicing activities of the RNA binding proteins FOX-1 and FOX-
2, members of the FOX family (feminizing gene on X), have been
revealed (reviewed in [6]). Both splicing regulators are conserved
across mammalian genomes and highly expressed in brain, heart
and muscle. Moreover, FOX-1 and FOX-2 are highly homolo-
gous, as both contain a conserved RNA recognition motif (RRM)
in the central region, which is responsible for binding the
UGCAUG motif of target RNAs, whereas the N- and C-terminal
regions are less conserved. Due to the use of tissue-specific
promoters and alternative splicing, several FOX variants have
been identified, some of these have a specific C-terminal sequence
RF(A/T)PY, which likely serves as a conserved nuclear localiza-
tion signal of this protein family (reviewed in [6]). In contrast,
FOX variants with different C-terminal endings are found to be
predominantly cytoplasmic potentially leading to different cellular
functions [7,8].
Interestingly, a global computational prediction utilizing the
FOX-binding motif UGCAUG resulted in a defined regulatory
splicing network, which comprises more than thousand FOX-1/
FOX-2 targets with enrichment in genes implicated in neuromus-
cular processes [9]. Of note, most of these target genes have been
linked to various human genetic disorders, such as neurological,
neurodegenerative or heart disorders amongst others, or are
encoding splicing factors per se [6,9,10]. Depending upon the
presence of this motif in upstream or downstream intronic flanking
regions, binding of FOX-1 or FOX-2 represses or enhances exon
inclusion, respectively (reviewed in [6]). Besides, mutations in
FOX-1 or its abnormal expression have been found in patients
with epilepsy, mental retardation, autism and heart disease
[11,12,13]. FOX-2 has been found differentially spliced in breast
cancer cells and was identified as a novel hub gene in a colon
cancer-specific gene network [14,15]. Interestingly, both FOX-1
and FOX-2, also known as A2BP1 (ataxin-2 binding protein 1)
and RBM9 (RNA binding motif protein 9), have been identified as
interaction partners of ataxin-1 (ATXN1), which is implicated in
spinocerebellar ataxia type 1 (SCA1) [16]. This disease belongs to
the family of so-called polyglutamine disorders that further
comprises Huntington’s disease, spinobulbar muscular atrophy,
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type 2, 3, 6, 7 & 17. All usually strike in late midlife and are
characterized by progressive neuronal dysfunction and loss of
specific neuronal populations. Causative for these disorders is an
expansion of the trinucleotide repeat CAG in otherwise unrelated
genes encoding an enlarged polyglutamine region in the disease-
causing proteins, for which the cellular functions are yet not clearly
understood [17,18,19]. The gene causative for SCA1 has been
cloned and identified on chromosome 6p23 and termed ATXN1
[20,21]. Normal ATXN1 alleles comprise 4–39 CAG repeats,
whereas alleles of SCA1 patients comprise 40–83 CAG repeats
leading to an expanded polyglutamine region in the N-terminal
part of ATXN1 [22,23,24]. This mutant protein accumulates in
nuclear inclusions that are detected in post-mortem brain tissue of
SCA1 patients and transgenic SCA1 mouse models representing
a neuropathological hallmark of SCA1 [22,24]. Moreover, these
nuclear ATXN1 inclusions are the source for the recruitment of
other cellular proteins and aberrant protein-protein interactions
thereby contributing to cellular dysfunction [25,26,27,28,29,30].
Interestingly, an interaction between FOX-1 and ataxin-2
(ATXN2), the disease protein in another SCA, spinocerebellar
ataxia type 2 (SCA2), has been reported as well [16,31]. Notably,
interactions between FOX-1 and FOX-2 and other ataxia-causing
proteins have been identified, indicating that both splicing factors
are part of a main hub in a human ataxia protein network [16].
Thus, some of the human inherited ataxias might represent RNA
splicing disorders as proposed or demonstrated for other
neurodegenerative and neurological disorders, since alternative
splicing is particularly prevalent in the brain [16,32]. This is
further supported by the finding that genes implicated in RNA
binding and processing modify neurodegeneration in transgenic fly
models of polyglutamine disorders [33,34].
In this study we set out to functionally characterize the
interaction between FOX-2 and ATXN1 that has been originally
identified in a high-throughput yeast-2-hybrid analysis [16], and
the effect of ATXN1 overexpression on FOX-2 localization and
splicing activity.
Results
Interaction between ATXN1 and FOX-2 variants
As mentioned before, FOX-2 has been shown to be part of
a main hub found in a protein-protein interaction network for
ataxia-causing proteins that have been implicated in more than 20
different inherited cerebellar ataxias [16]. Interestingly, ATXN1
has been identified as one interaction partner of FOX-2 [16]. To
further characterize this interaction, we first carried out directed
yeast-2-hybrid (Y2H) analyses. For this, we generated different
prey constructs for ATXN1, which are schematically shown in
Fig. 1A (left panel). The plasmids pACT-ATXN1-NTQ30 and
pACT-ATXN1-NTQ82 encode the N-terminal region of
ATXN1, which comprises the polyglutamine region with 30 or
82 glutamines, representing normal and disease state, respectively.
Plasmid pACT-ATXN1-AXH encodes the AXH-domain of
ATXN1, an RNA-binding motif, which is implicated in the self-
association of ATXN1 [35]. Furthermore, the transcriptional
repression activity of ATXN1 relies on this domain [36]. Plasmid
pACT-ATXN1-CT encodes the C-terminal portion of the pro-
tein, including the AXH-domain. On the other hand, we
generated bait constructs for expression of a predominantly
nuclear and cytoplasmic FOX-2 variant, termed FOX-2V1 and
FOX-2cyt, respectively, which are schematically shown in Fig. 1A
(right panel; please see Material and Methods and Fig. S1 for
further details). The rationale behind this is based on the fact that
use of alternative promoters and alternative splicing patterns
generate diverse FOX protein variants with different N- or C-
terminal regions that do not preferentially localize to the nucleus
but also to the cytoplasm [7,8,37]. Both variants used show
differences exclusively in the C-terminal region resulting in the loss
of the putative nuclear localization signal in the variant FOX-2cyt
(Fig. S1A). Moreover, we decided to make use of both FOX-2
variants, since ATXN1 has been found to shuttle between the
nucleus and the cytoplasm [25]. First of all we performed Y2H
analyses to exclude the possibility that the bait proteins LexA-
FOX-2V1 and LexA-FOX-2cyt as well as the ATXN1 prey
proteins per se led to the activation of the analyzed reporter genes.
First, bait plasmids pBTM-FOX-2V1 and pBTM-FOX-2cyt
encoding fusion proteins of the DNA binding domain LexA and
the FOX-2 variants, and the prey vector pACT encoding the
activation domain (AD) were co-transformed. Secondly, the bait
vector pBTM encoding the DNA binding domain LexA was co-
transformed with the prey constucts pACT-ATXN1-NTQ30,
pACT-ATXN1-NTQ82, pACT-ATXN1-AXH, or pACT-
ATXN1-CT encoding the fusion proteins AD-ATXN1-
NT(Q30)1–576, AD-ATXN1-NT(Q82)1–576, AD-ATXN1-
AXH559–701, or AD-ATXN1-CT530–816, respectively. Consequent-
ly, the respective yeast transformants were isolated and analyzed
for reporter gene activity. Reporter gene activity was not observed
for all the combinations tested (Fig. 1B and Fig. 1C). In the second
step, we performed directed Y2H analyses to test for a potential
interaction between the two FOX-2 variants and ATXN1. We
observed that yeast cells expressing LexA-FOX-2V1 and AD-
ATXN1-NT(Q30)1–576 or AD-ATXN1-NT(Q82)1–576 exhibited
activity of the reporter genes (Fig. 1B). Interestingly, activity of
reporter genes was also detected for yeast cells expressing LexA-
FOX-2cyt and AD-ATXN1-NT(Q30)1–576 or AD-ATXN1-
NT(Q82)1–576 (Fig. 1C). Reporter gene activity was not observed
for yeast cells expressing LexA-FOX-2V1 or LexA-FOX-2cyt and
AD-ATXN1-AXH559–701 or AD-ATXN1-CT530–816, respectively.
We therefore concluded that an interaction between both FOX-2
variants and the N-terminal region of ATXN1 occurs in the Y2H
system.
To further validate the interaction between FOX-2 and
ATXN1, we performed co-immunoprecipitation (Co-IP) experi-
ments using lysates prepared from HEK293T cells overexpressing
FLAG-ATXN1-Q30 or lysates from non-transfected HEK293T
cells for the detection of endogenous interactions. As shown in
Fig. 1D (left panel), FLAG-ATXN1-Q30 protein was precipitated
with an antibody directed against FOX-2. A minimal amount of
protein was precipitated in the control sample lacking primary
antibody. In addition, endogenous ATXN1 was enriched with an
antibody directed against FOX-2 that recognizes a number of
FOX-2 protein variants as well (Fig. 1D, right panel). Thus,
ATXN1 is found in association with FOX-2 in mammalian cells.
Nuclear ATXN1 inclusions affect FOX-2 localization
To further confirm that the protein-protein interaction between
FOX-2 and ATXN1 is valid, we next carried out localization
studies. The important aspect here is that ATXN1 has been
reported to be predominantly nuclear, however shuttling of
ATXN1 between nucleus and cytoplasm has been reported
[25,38]. In line with this, we observed in our Y2H analyses that
ATXN1 is able to interact with the mainly cytoplasmic FOX-2cyt
splice variant as well. HeLa cells were co-transfected with the
mammalian expression plasmids pcDNA1-FLAG-SCA1-Q30 or
pcDNA1-FLAG-SCA1-Q82 to express full-length ATXN1 with
30 or 82 consecutive glutamines and pCMV-HA-FOX-2V1 or
pCMV-MYC-FOX-2cyt, respectively. Afterwards, cells were pre-
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Methods. We observed that the protein HA-FOX-2V1 displayed
a predominantly diffuse nuclear localization, whereas MYC-FOX-
2cyt was evenly distributed in the cytoplasm (Fig. S1B). Moreover,
we detected that in cells overexpressing the proteins FLAG-
ATXN1-Q30 or FLAG-ATXN1-Q82 the variant HA-FOX-2V1
co-localized with the nuclear inclusions formed by these proteins
(Fig. 2A). These nuclear inclusions, which are a pathological
hallmark in SCA1, are heterogeneous and display diverse body
morphology [22,24]. We observed that co-localization of FOX-2
was more prominent with larger inclusions, but co-localization was
also observed with smaller inclusions formed by FLAG-ATXN1-
Q30 and FLAG-ATXN1-Q82. Interestingly, the cytoplasmic
MYC-FOX-2cyt variant co-localized with both larger and smaller
nuclear ATXN1 inclusions as well (Fig. 2B). To further investigate
the specificity of this co-localization, we included the protein
TIAR (TIA1 cytotoxic granule-associated RNA binding protein-
like 1), a splicing regulator comprising RRM domains like FOX-2
[39,40]. For this, HeLa cells were co-transfected with the
mammalian expression plasmids pcDNA1-FLAG-SCA1-Q30 or
pcDNA1-FLAG-SCA1-Q82 and pCMV-MYC-TIAR and pre-
pared as described. In this case, we observed that the presence of
nuclear ATXN1 inclusions had no effect on the localization of
TIAR (Fig. 2C), indicating that the mis-localization of FOX-2
noticed in the presence of nuclear ATXN1 inclusions is specific,
and is not based on unspecific trapping effects of RNA binding
proteins.
Furthermore, we investigated whether the observed mis-
localization of FOX-2 in the presence of ATXN1 inclusions holds
true for endogenous FOX-2 protein. Again, HeLa cells were
transfected with expression plasmids pcDNA1-FLAG-SCA1-Q30
or pcDNA1-FLAG-SCA1-Q82. Of note, we observed that the
localization of endogenous FOX-2 protein (Fig. 3A) was affected,
since it co-localized with nuclear ATXN1 inclusions as well
(Fig. 3B). Once more, co-localization of FOX-2 seemed to be more
prominent with larger nuclear ATXN1 inclusions. To further
Figure 1. ATXN1 interacts with FOX-2 splice variants. (A) Schematic view of ATXN1 and the regions used in the Y2H analyses (left) and FOX-2
variants (right). Prey plasmids pACT-ATXN1-NTQ30 or pACT-ATXN1-NTQ82 cover amino acids 1–576, pACT-ATXN1-AXH amino acids 559–701, and
pACT-ATXN1-CT amino acids 530–816. Bait plasmid pBTM-FOX-2V1 covers amino acids 1–380 of variant 1, including the putative NLS in the C-terminal
region, and pBTM-FOX-2cyt covers amino acids 1–391 of the cytoplasmic FOX-2 variant. Different C-terminal regions of both FOX-2 variants are
highlighted in blue and green. (B; C) For directed Y2H analyses yeast strain L40ccua was co-transformed with the relevant bait and prey plasmids,
and transformants were selected and spotted onto selective media or membrane to analyze activity of the reporter genes. (D) For Co-IP experiments,
HEK293T cell lysates derived from cells overexpressing FLAG-ATXN1-Q30 (left panel) or HEK293T cell lysates (right panel) were incubated with an
antibody directed against FOX-2 (Bethyl or Abnova, respectively). Cell lysates incubated without primary antibody served as controls. Then,
membranes were treated with an antibody directed against the FLAG tag or ATXN1 to detect precipitated protein.
doi:10.1371/journal.pone.0037985.g001
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37985Figure 2. The FOX-2 splice variants FOX-2V1 and FOX-2cyt co-localize with nuclear ATXN1 inclusions. Confocal microscopy of HeLa cells
transfected with (A) pCMV-HA-FOX-2V1 and pcDNA1-FLAG-SCA1-Q30 or pcDNA1-FLAG-SCA1-Q82, or (B) pCMV-MYC-FOX-2cyt and pcDNA1-FLAG-
SCA1-Q30 or pcDNA1-FLAG-SCA1-Q82, and (C) pCMV-MYC-TIAR and pcDNA1-FLAG-SCA1-Q30 or pcDNA1-FLAG-SCA1-Q82, respectively. Forty-eight
hours post transfection cells were fixed and prepared for microscopic analyses. Proteins were visualized using the respective antibodies against the
tag as described in Material and Methods. Nuclei were stained using Hoechst. Bars represent 20 mm.
doi:10.1371/journal.pone.0037985.g002
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cells. In addition to HeLa cells, this cell line has been used to study
formation of ATXN1 inclusions as well as ATXN1-induced cell
death. Moreover, it was demonstrated that both cell lines
reproduce molecular mechanisms contributing to SCA1 patho-
genesis in the cerebellum [25,27,41,42]. Accordingly, we trans-
fected HEK293T cells with expression plasmids pcDNA1-FLAG-
SCA1-Q30 or pcDNA1-FLAG-SCA1-Q82 and prepared the cells
for microscopy. As observed in HeLa cells, endogenous FOX-2 co-
localized with nuclear inclusions formed by FLAG-ATXN1-Q30
and FLAG-ATXN1-Q82 (Fig. S2). Thus, overexpression of
normal and mutant ATXN1 caused mis-localization of endoge-
nous FOX-2 proteins under the chosen experimental settings.
Again, to further validate the specificity of this mis-localization, we
also analyzed the localization of endogenous TIAR protein in the
presence of nuclear ATXN1 inclusions. As shown in Fig. 3C, we
observed that nuclear ATXN1 inclusions had no effect on nuclear
localization of TIAR under the chosen conditions.
In the next step, we wanted to investigate if the polyglutamine
region is important for the mis-localization of FOX-2. Here we
took advantage of the plasmids Tsai and colleagues generated,
encoding ATXN1 lacking the polyglutamine stretch or comprising
30 or 82 consecutive glutamines fused to the cyan fluorescent
protein [43]. HeLa cells were transfected with the respective
constructs and CFP-ATXN1 and FOX-2 localization was
examined by confocal microscopy. As described by Tsai and
colleagues, overexpression of CFP-ATXN1-Q0, CFP-ATXN1-
Q30 and CFP-ATXN1-Q82 led to the formation of nuclear
inclusions (Fig. 4). In all cases prominent co-localization of FOX-2
with larger ATXN1 inclusions was detected, demonstrating that
the polyglutamine region within ATXN1 is not required for the
observed co-localization between FOX-2 and ATXN1.
FOX-2 splicing activity is affected in the presence of
nuclear ATXN1 inclusions
Since mis-localization of FOX-2 was observed in the presence of
nuclear ATXN1 inclusions, we investigated next whether ATXN1
overexpression has an effect on FOX-2 splicing activity. Here, we
focused on one target gene of FOX-2 dependent splicing, MAP3K7
Figure 3. FOX-2 co-localizes with nuclear ATXN1 inclusions. (A) Endogenous localization of FOX-2 in HeLa cells visualized with an antibody
directed against FOX-2 (Bethyl). (B; C) HeLa cells expressing normal and mutant ATXN1 were fixed forty-eight hours post transfection. Endogenous
proteins were visualized using respective antibodies against (B) FOX-2 (Bethyl) and FLAG or (C) TIAR and FLAG as described. Nuclei were stained
using Hoechst. Bars represent 20 mm.
doi:10.1371/journal.pone.0037985.g003
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has been reported that FOX-2 depletion results in increased
inclusion of exon 12 in the MAP3K7 transcript [10]. After
transfection of HEK293T cells with plasmids pcDNA1-FLAG-
ATXN1-Q30 or pcDNA1-FLAG-ATXN1-Q82 or with siRNA
molecules for knock-down of FOX-2 and respective controls, cells
were lysed, RNA was extracted and RT-qPCR performed as
described. Notably, we observed an increase of MAP3K7
transcript with inclusion of exon 12 when either normal or
mutant ATXN1 were overexpressed compared to the vector
control, increasing the ratio between inclusion and exclusion of
MAP3K7 exon 12 by 2.7- or 2.0-fold, respectively (Fig. 5B). Here,
we would like to point out that variations in ATXN1 transcript
levels of normal and mutant ATXN1 could be accountable for the
observed difference in the ratio between inclusion and exclusion of
MAP3K7 exon 12 (Fig. 5C). As control, we also analyzed the effect
of ATXN1 overexpression on FOX-2 transcription. We did not
detect any alterations under the chosen conditions (data not
shown). Moreover, a 6.3- or 15.6-fold increase in the ratio between
inclusion and exclusion of MAP3K7 exon 12 was also observed for
FOX-2 knock-down in HEK293T and HeLa cells, respectively
(Fig. 5D). The transcript level of FOX-2 was reduced to
approximately 20% (Fig. 5E). Thus, FOX-2 dependent splicing
is affected by ATXN1 overexpression.
Interaction of FOX-2 splice variants with ATXN2
In addition to the interaction between ATXN1 and FOX-2, an
interaction between the FOX-2 paralog, FOX-1 (A2BP1),
ATXN1 and ATXN2 has been reported [16] (Fig. 6A). Based
on this, we decided to investigate whether ATXN2 and FOX-2
are also found in association. First, we carried out directed Y2H
analyses using both FOX-2 variants and ATXN2 regions as
indicated in Fig. 6B. Again, we first excluded that the bait LexA-
ATXN2 fusion proteins and prey AD-FOX-2 fusion proteins per se
lead to the activation of the reporter genes by co-transformation of
the respective bait and prey plasmids. Reporter gene activity was
not detected (Fig. 6C; D). Yeast cells expressing the fusion proteins
LexA-ATXN2254–476 and AD-FOX-2V1 (Fig. 6C) exhibited
activity of reporter genes as well as yeast cells expressing LexA-
ATXN2816–1312 and AD-FOX-2cyt (Fig. 6D), indicating a direct
interaction between FOX-2 variants and ATXN2 as well.
Interestingly, we did not detect an interaction between the fusion
proteins LexA-ATXN2(Q22)1–396 or LexA-ATXN2(Q79)1–396,
which comprise the N-terminal region of ATXN2 containing the
polyglutamine stretch, and FOX-2 variants suggesting that the
polyQ region is not critical for this interaction. In addition, Co-IP
experiments were carried out, demonstrating that endogenous
ATXN2 was precipitated from HeLa cell lysate using an antibody
against FOX-2 (Fig. 6E). Thus, besides the interaction with
ATXN1, FOX-2 is also found in association with ATXN2.
Since an accumulation of ATXN2 in cells with nuclear ATXN1
inclusions has been observed in a transgenic SCA1 fly model as
well as in human SCA1 neurons [28], we finally carried out co-
localization studies to investigate whether ATXN2 co-localizes
with ATXN1 in the cell line used. We observed that HeLa cells
overexpressing ATXN2 in combination with normal or mutant
ATXN1 proteins exhibited co-localization of ATXN2 with
ATXN1 inclusions as well (Fig. 6F).
In addition, ATXN2 but also a number of RNA-binding
proteins with RRM-domains are part of cytoplasmic stress
granules under conditions of cellular stress [44,45]. Therefore,
we wanted to further investigate the localization of both FOX-2
splice variants under such conditions. For this, HeLa cells were
transiently transfected with expression vectors encoding HA-FOX-
2V1 or MYC-FOX-2cyt, treated with arsenite and prepared for
microscopic analysis as described. As shown in Fig. S3A, both
FOX-2 variants accumulated in cytoplasmic foci in arsenite-
treated cells that co-localized with ATXN2, indicating that both
FOX-2 splice variants are part of stress granules. Furthermore, we
also monitored endogenous FOX-2 protein localization in HeLa
cells. We observed that FOX-2 exhibited a predominantly nuclear
localization in untreated and arsenite-treated cells (Fig. S3B).
However, quite a few FOX-2 positive cytoplasmic foci were
observed in arsenite-treated cells that are also positive for ATXN2
and for another stress granule marker protein analyzed, TIAR
[45,46], further demonstrating that FOX-2 is indeed a component
of stress granules.
FOX-2 regulates splicing of ATXN2 transcripts
Remarkably, ATXN2 has been described as a modulator of
SCA1 pathogenesis [28]. Therefore it is quite interesting that the
SCA2 gene bears two putative FOX-binding sites , 30–100
nucleotides downstream of exon 18 in the ATXN2 transcript
(Fig. 7A) [9], suggesting that FOX-2 could potentially be involved
in ATXN2 pre-mRNA splicing. To investigate this, we decided to
perform RNAi experiments and to analyze the effect of FOX-2
depletion on splicing of exon 18 of the ATXN2 transcript. After
transfecting HEK293T or HeLa cells with siRNA molecules
specific for FOX-2 or with control siRNA, RNA was isolated and
RT-qPCR performed. As shown in Fig. 7B, reduced levels of
FOX-2 led to an enrichment of ATXN2 transcript lacking exon
18 thereby decreasing the ratio between inclusion/exclusion of
exon 18 in ATXN2 transcripts in both cell lines to 0.086-fold or
0.026-fold in comparison to controls, demonstrating that FOX-2 is
implicated in ATXN2 pre-mRNA splicing. To further confirm the
Figure 4. Co-localization of FOX-2 with nuclear ATXN1 inclu-
sions is independent of the polyglutamine region. Confocal
microscopy of HeLa cells transfected with CFP-ATXN1-Q0, CFP-ATXN1-
Q30 or CFP-ATXN1-Q82, respectively. Forty-eight hours post trans-
fection cells were fixed and prepared for microscopic analyses. FOX-2
protein was visualized using a specific antibody (Abnova). CFP
fluorescence was pseudo-coloured green. Nuclei were stained using
Hoechst. Bars represent 20 mm.
doi:10.1371/journal.pone.0037985.g004
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low abundance as suggested by the RT-qPCR experiments, we
analyzed a panel of cell lines for the existence of ATXN2
transcripts lacking exon 18 with the described primer pair and
obtained respective amplicons, of which one was validated by
sequencing (Fig. 7C). Interestingly, skipping of exon 18 of ATXN2
transcripts leads to a premature stop codon. This would result in
a different C-terminal region, and such a variant has been
annotated as protein-coding in ENSEMBL (ENST00000550104).
Consequently, we also investigated the influence of ATXN1
overexpression, since we had observed an effect on splicing
activities of FOX-2. For this, HEK293T cells were transiently
transfected with plasmids pcDNA1-FLAG-SCA1-Q30 or
pcDNA1-FLAG-SCA1-Q82, or an empty vector as control,
RNA was isolated and RT-qPCR experiments were performed.
We observed that overexpression of FLAG-ATXN1-Q30 or
FLAG-ATXN1-Q82 resulted in a decrease of the ratio between
inclusion/exclusion of exon 18 in ATXN2 transcripts to 0.26-fold
or 0.33-fold (Fig. 7D). Thus, FOX-2 dependent splicing of
ATNX2 transcripts is affected by ATXN1 overexpression.
Discussion
In this study, we functionally analyzed the interaction between
ATXN1 and FOX-2 splice variants. The FOX genes are highly
diverse due to the use of alternative promoters and alternative
splicing, and the respective splice variants exhibit nuclear as well as
cytoplasmic localization [8,37]. As mentioned, FOX-2 is highly
expressed in the brain and in the cerebellar cortex suggesting high
splicing activity in this location [7,47]. Therefore, it is interesting
that FOX-2 localization and splicing activity was affected in the
presence of nuclear ATXN1 inclusions, which are detected in
post-mortem brain tissue of SCA1 patients and transgenic SCA1
mouse models [22,24]. Given that the formation of nuclear
Figure 5. ATXN1 overexpression affects FOX-2 splicing activity. (A) Schematic view of a partial genomic region of the MAP3K7 gene. Exons
are represented by white boxes, the intronic regions by a black line. The FOX-binding sites are shown as black rectangles. (B; C) Total RNA was
isolated from HEK293T cells transiently overexpressing ATXN1 with 30 or 82 glutamines. (B) Splicing of the MAP3K7 exon 12 was analyzed by RT-
qPCR. Inclusion/exclusion ratio of MAP3K7 exon 12 is illustrated. (C) ATXN1 overexpression was analyzed by RT-qPCR. ATXN1 transcript levels
detected in the vector control were set as value one. (D; E) Total RNA was isolated from HEK293T and HeLa cells that were either transfected with
FOX-2-specific siRNA or with control siRNA and splicing of the MAP3K7 exon 12 was analyzed by RT-qPCR. (D) Inclusion/exclusion ratio of MAP3K7
exon 12 is demonstrated. (E) FOX-2 reduction was analyzed by RT-qPCR in HeLa and HEK293T cells. Error bars indicate standard error of the mean.
doi:10.1371/journal.pone.0037985.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37985Figure 6. ATXN2 interacts with FOX-2 splice variants and co-localizes with nuclear ATXN1 inclusions upon overexpression. (A)
Schematic illustration of ATXN1 interactions. Black lines represent interactions reported by Lim and co-workers [16], the blue line represents the
investigated interaction in this study. (B) Schematic view of ATXN2 regions used in Y2H studies as described earlier [44,51,66]. (C; D) L40ccua yeast
cells expressing the corresponding LexA-ATXN2 and AD-FOX-2 fusion proteins were spotted onto selective media or membrane as indicated and the
activity of the reporter genes was monitored. (E) HeLa cell lysates were incubated with an antibody directed against FOX-2 (Bethyl) and membranes
were treated with an anti-ATXN2 antibody (BD-Biosciences) to detect precipitated protein. (F) HeLa cells were transfected with pCMV-MYC-ATXN2-
Q22 or co-transfected with pCMV-MYC-ATXN2-Q22 and pcDNA1-FLAG-SCA1-Q30 or pcDNA1-FLAG-SCA1-Q82, respectively. Forty-eight hours post
transfection cells were fixed and prepared for microscopic analyses. Nuclei were stained using Hoechst. Bars represent 20 mm.
doi:10.1371/journal.pone.0037985.g006
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glutamine stretch [25,43], we did not observe a significant
difference in the co-localization of FOX-2 and normal or mutant
ATXN1 in the cell lines tested. Moreover, overexpression of
normal ATXN1 leads to neurodegeneration in animal models as
well, although to a much lesser extent than mutant ATXN1 [34].
Finally, one should bear in mind that quantitative distinctions are
not feasible in our cell line models.
Interestingly, defects in the cellular RNA metabolism have been
linked to SCA1 pathogenesis. On one hand, ATXN1 itself is
a RNA binding protein whose binding to RNA is affected by the
length of the polyglutamine stretch [48], and gene products
implicated in binding and processing of RNA have been shown to
modify neurodegeneration in transgenic SCA1 fly models [33,34].
On the other hand, complex formation between mutant ATXN1
and the RNA binding motif protein 17 (RBM17) is increased,
thereby lowering the complex between normal ATXN1 and
capicua [27]. Co-expression of human RBM17 and mutant
ATXN1 worsened the ATXN1-induced eye phenotypes in
a transgenic SCA1 fly model [27]. Initially, RBM17 was identified
by mass spectrometry to be part of the human spliceosome [49],
but has been shown to regulate apoptosis through alternative
splicing of FAS, too [50]. Interestingly, an interaction between
ATXN1 and another splicing factor, U2AF65, has been reported
as well [26]. Here, overexpression of normal ATXN1 has an
enhancing effect on U2AF65-mediated splicing, whereas mutant
ATXN1 has not; potentially due to interference of the expanded
polyglutamine stretch with molecular recognition or due to
recruitment or trapping of this factor in nuclear inclusion formed
by mutant ATXN1 [26]. Moreover, the mRNA export factor
TAP/NXF1 has been shown to be recruited into nuclear ATXN1
inclusions [25].
Another intriguing aspect is that ATXN2, a protein itself
involved in the cellular RNA metabolism [44,51,52], has been
shown to modulate SCA1 pathogenesis, since ATXN2 over-
expression enhances, whereas ATXN2 depletion reduces ATXN1-
induced toxicity in a fly model [28]. Moreover, nuclear
accumulation of ATXN2 was observed in post-mortem brain of
a SCA1 patient and correlated to SCA1 pathogenesis [28]. In light
of this, the finding that splicing of ATXN2 transcripts is affected
by FOX-2 depletion as well as by overexpression of normal and
mutant ATXN1 is interesting and it is quite tempting to speculate
that alterations in ATXN2 transcripts and their cellular con-
sequences affect SCA1 pathogenesis (Fig. 8). Although we used
non-neuronal cell lines such as HEK293T and HeLa cells in our
study, the results obtained could be quite relevant for SCA1, since
both reproduce molecular mechanisms contributing to SCA1
pathogenesis in the cerebellum [25,27,41,42]. So far, some
ATXN2 splice variants have been described that might fulfill
different functions [52,53,54], e.g. in the central nervous system
the ATXN2 full-length transcript is predominantly present in the
brain and spinal cord, while expression of a ATXN2 splice variant
lacking exon 10 is more prominent in the cerebellum [54].
Therefore, further insight into the cellular function of different
ATXN2 splice variants and their regulation and whether and how
this relates to mechanisms underlying SCA1 will be an interesting
aspect in the future.
On the other hand, these insights might also be valuable with
regards to the polyglutamine disorder SCA2, in which ATXN2
represents the causative protein. In this study, we have provided
first evidence that both FOX-2 variants directly interact with
ATXN2 as well. Thus, it will be interesting to investigate the
biological consequence of the ATXN2/FOX-2 interaction and
whether mutant ATXN2 has an impact on FOX-2 splicing
activity in general and particularly on ATXN2 transcripts per se.
Notably, we observed an interaction between the predominantly
nuclear FOX-2 variant and the ATXN2 region comprising the
LSm domain that forms the structural core of spliceosomal small
Figure 7. Splicing of ATXN2 transcripts is affected by both,
reduced FOX-2 levels and ATXN1 overexpression. (A) Schematic
view of a partial genomic region of the SCA2 gene. Exons are
represented by white boxes, the respective intronic regions by a black
line. The two potential FOX-binding sites 40 bp downstream of exon 18
are shown as black rectangles. (B) HEK293T and HeLa cells were either
transfected with FOX-2-specific siRNA or with control siRNA. Sub-
sequently, total RNA was isolated and RT-qPCR experiments were
performed as described in Material and Methods. Inclusion/exclusion
ratio of ATXN2 exon 18 is shown. Error bars indicate standard error of
the mean. (C) Schematic view of a region of ATXN2 transcripts lacking
exon 18 (upper panel) and the primers used for its detection in various
cell lines as indicated (lower panel). (D) HEK293T cells were transfected
with pcDNA1-FLAG-SCA1-Q30 or pcDNA1-FLAG-SCA1-Q82 and pro-
cessed as described in (B).
doi:10.1371/journal.pone.0037985.g007
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complexes, implicating ATXN2 per se in splicing events [55].
Accordingly, first evidence for a nuclear localization of ATXN2
has been provided [28,56]. On the other hand, the predominantly
cytoplasmic FOX-2 variant was found to interact with the C-
terminal region of ATXN2 containing the PAM motif. Several
splicing factors were also found to function in the cytoplasm or
were detected in stress granules, cytoplasmic sites existing in
mammalian cells under various stress conditions that are involved
in translational control [57,58,59]. In line with these observations,
we discovered that FOX-2, like ATXN2, is a component of stress
granules. Interestingly, the Xenopus homolog of FOX-2, XRbm9, is
part of a cytoplasmic polyadenylation complex [60]. Thus, it will
be interesting in the future to dissect the cellular functionality of
the interactions between the different FOX-2 and ATXN2
variants likely occurring in different compartments.
Splice variants of other polyglutamine proteins have been
described at the transcript as well as protein level as pointed out
recently by Harris and colleagues [61]. For SCA3, a number of
ataxin-3 splice variants have been identified [62,63], and in-
terestingly, for two variants, differences in their aggregation
properties have been demonstrated [61]. Moreover, cell-type-
specific alternative splicing of ataxin-6 is likely to contribute to
SCA6 pathogenesis [64]. For SCA7, a different cellular localiza-
tion of a novel ataxin-7 variant in patient tissue has been reported
[65]. These findings strongly indicate that alternative splicing of
disease-causing genes per se is implicated in the pathogenesis of
polyglutamine disorders. Since several polyglutamine or ataxia-
causing proteins are also connected in a protein-protein in-
teraction network, regulatory effects of splice variants at the
protein level are likely to take place as well [16]. Since there is
evidence that splicing differs in health and disease, isoform-specific
targeting could be a promising therapeutic avenue to approach.
Materials and Methods
Plasmids
Plasmid pJET1.2-FOX-2cyt was generated by subcloning a DNA
fragment generated via PCR using the oligonucleotide pair FOX-
2-s-SalI and FOX-2-as-NotI and human fetal brain library
(Clontech; Mountain View, USA) as template. This FOX-2
variant is identical to the FOX-2 transcript variant 1
(ENST00000449924), but contains an additional 32 bp insertion
between exon 12 (ENSE00001578447) and exon 13
(ENSE00001611944), which corresponds to an annotated exon
(ENSE00001553845) (Fig. S1A; Accession number AB649123,
DDBJ). This insertion results in a frame-shift that generates an
alternative C-terminal region lacking the hydrophobic PY nuclear
localization signal (RF(A/T)PY) that is conserved within the FOX
protein family and required for nuclear localization [6,7].
Confocal microscopy demonstrated that HA-FOX-2V1 containing
the conserved nuclear localization signal RF(A/T)PY was pre-
dominantly located in the nucleus, whereas MYC-FOX-2cyt
mainly displayed a cytoplasmic localization (Fig. S1B). For
generating the Y2H plasmids pACT-FOX-2cyt and pBTM-
FOX-2cyt, plasmid DNA pJET1.2-FOX-2cyt was treated with the
restriction endonucleases SalI and NotI. Afterwards, the respective
DNA fragment was isolated and subcloned into the SalI/NotI sites
of pBTM117c or pACT4-1b, respectively.
Y2H plasmids pBTM-ATXN1-NTQ30, pBTM-ATXN1-
NTQ82, pBTM-ATXN1-AXH, and pBTM-ATXN1-CT were
created by PCR using primer pairs ATXN1-NT-s-SalI and
ATXN1-NT-as-NotI, ATXN1-AXH-s-SalI and ATXN1-AXH-
as-NotI, or ATXN1-CT-s-SalI and ATXN1-CT-as-NotI, respec-
tively, and pcDNA1-FLAG-SCA1-Q30 or pcDNA1-FLAG-
SCA1-Q82 as template DNA (kind gift of Flaviano Giorgini,
University of Leicester). Afterwards, resulting DNA fragments
were treated with SalI and NotI and subcloned into the SalI/NotI
sites of pBTM117c. For generating Y2H plasmids pACT-
ATXN1-NTQ30, pACT-ATXN1-NTQ82, pACT-ATXN1-
AXH or pACT-ATXN1-CT, respective pBTM plasmids were
treated with SalI and NotI. Resulting DNA fragments were
subcloned into the SalI/NotI sites of pACT4-1b, respectively.
The mammalian expression construct pCMV-MYC-FOX-2cyt
was created by treating plasmid pBTM-FOX-2cyt with SalI and
NotI. Subsequently, the relevant DNA fragment was purified and
subcloned into the SalI/NotI sites of the mammalian expression
vector pCMV-MYC (Clontech; Mountain View, USA). The
mammalian expression plasmid pCMV-HA-FOX-2V1 encoding
variant 1 of FOX-2 (ENST00000449924) was generated by
a multi-step PCR using pCMV-MYC-FOX-2cyt as template. First
PCR was performed using primer pair FOX-2-s-SalI and FOX-2-
nuc-as1-E12-E13-blunt, which has been designed to contain the
last 20 nucleotides of exon 12 in combination with the first 11
nucleotides of exon 13 of the FOX-2 sequence. In a second PCR
step primer pair FOX-2-nuc-s1-E12-E13-blunt, which has been
designed to contain the last 10 nucleotides of exon 12 and the first
21 nucleotides of exon 13 of the FOX-2 sequence, and FOX-2-
Figure 8. Schematic model of FOX-2 and ATXN1 effects on ATXN2 transcript. The SCA2 gene bears two putative FOX-binding sites
downstream of exon 18 in the ATXN2 transcript as illustrated. Under normal conditions, FOX-2 binding resulted in inclusion of exon 18, whereas
depletion of FOX-2 or overexpression of ATXN1 resulted in increased levels of ATXN2 transcripts lacking exon 18.
doi:10.1371/journal.pone.0037985.g008
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purified and mixed to equal concentrations and used as template
in a final PCR step with primer pair FOX-2-s-SalI and FOX-2-
nuc-as1-NotI resulting in a DNA fragment lacking the 32
nucleotide sequence insertion (ENSE00001553845) present in
pCMV-MYC-FOX-2cyt. After purification, this DNA fragment
was subcloned into vector pJET1.2 to generate plasmid pJET1.2-
FOX-2V1. Next, plasmid pJET1.2-FOX-2V1 was treated with the
restriction endonucleases SalI and NotI and the corresponding
DNA fragment was isolated and subcloned into the SalI/NotI sites
of the mammalian expression vector pCMV-HA or the Y2H
vectors pBTM117c and pACT4-1b, to generate plasmids pCMV-
HA-FOX-2V1, pBTM-FOX-2V1 and pACT-FOX-2V1, respec-
tively.
The mammalian expression construct pCMV-MYC-TIAR
(variant 2) was generated by PCR using the oligonucleotide pair
TIAR-s-SalI and TIAR-as-NotI and human fetal brain library
(Clontech; Mountain View, USA) as template. The amplified
DNA fragment was subcloned into vector pCMV-MYC.
The Y2H plasmids encoding different LexA-ATXN2 fusion
proteins and the mammalian expression plasmid pCMV-ATXN2-
Q22 were described earlier [44,51,66]. Mammalian expression
plasmids encoding CFP-ATXN1-Q0, CFP-ATXN1-Q30 and
CFP-ATXN1-Q82 were a kind gift of C.C. Tsai (Robert Wood
Johnson Medical School, New Jersey, USA).
Primers used in this study are listed in Table 1 and constructs
were validated by sequencing.
Yeast Two Hybrid analysis
Yeast strain L40ccua was co-transformed with the bait
constructs pBTM-FOX-2V1 or pBTM-FOX-2cyt and the series
of pACT-ATXN1 prey constructs, or with the different pBTM-
ATXN2 constructs and pACT-FOX-2V1 or pACT-FOX-2cyt,
respectively. Afterwards, transformants grown on SD media
lacking tryptophan and leucine were isolated and analyzed for
the activity of the reporter genes. For this, yeast cells grown in the
respective liquid media were spotted onto solid medium lacking
leucine and tryptophan and onto solid medium lacking trypto-
phan, leucine, uracil and histidine. For analyzing the activity of the
LacZ reporter gene, cells were spotted onto a nylon membrane
(Micron Separations Inc.; Westboro, USA). Growth on plates was
analyzed after 3–5 days. For analysis of LacZ reporter gene
activity, the membrane was incubated in liquid nitrogen and
subsequently placed on Whatman paper saturated with X-Gal
buffer (phosphate buffer pH 7.0, 0.15% X-Gal, 10 mM DTT) for
four to six hours at 37uC.
Cell cultivation and transfection
HeLa and HEK293T cells (ATCC, Manassas, USA) were
cultivated in Dulbecco’s modified Eagle medium (Gibco-Invitro-
gen; Paisly, UK) supplemented with 100 U/ml Penicillin, 100 mg/
ml G-Streptomycin (Biochrom; Berlin, Germany) and 10% fetal
bovine serum (Biochrom; Berlin, Germany) at 37uC and 5% CO2.
For transient transfections, cells were grown in 12- or 24-well
plates to a confluence of 50–70%. Then, cells were transfected
with 1–2 mg of the corresponding mammalian expression plasmids
using 3 or 6 ml PEI (Polyethylenimine, Polysciences, Inc.;
Warrington, USA) or 2.5 or 5 ml PolyFect (Qiagen; Hilden,
Germany), respectively. To allow transient expression of proteins,
cells were incubated for 24–48 hours at 37uC and 5% CO2.
Protein lysates and Co-Immunoprecipitation
Co-IP experiments were carried out as described earlier [51,66].
Briefly, for the association studies between ATXN1 and FOX-2,
HEK293T cells overexpressing FLAG-ATXN1-Q30 or non-
transfected HEK293T cells were washed once with PBS, treated
for 10 minutes with lysis buffer A [10 mM HEPES pH 7.4 (USB
corporation; Cleveland, USA), 10 mM NaCl, 3 mM MgCl2
(Merck; Darmstadt, Germany), 1 mM DTT (Sigma; St. Louis,
USA), 1/7 complete Mini EDTA-free Protease Inhibitor Cocktail
(Roche; Mannheim, Germany)], and lysates were passed ten times
through a needle. Afterwards, 500 mM NaCl was added, samples
were incubated for 20 minutes at 4uC on a rotation wheel and
cleared by centrifugation (5 minutes, 5000 rpm, 4uC; rotor:
eppendorf FA-45-24-11). Then, the supernatant fractions were
transferred to a new tube. The pellet fractions were treated with
lysis buffer B [10 mM HEPES pH 7.4, 300 mM NaCl, 20 mM
MgCl2, 1 mM DTT, 1/7 complete Mini EDTA-free Protease
Inhibitor Cocktail, 0.2 U DNase (Sigma; St. Louis, USA)] for
30 minutes at 37uC, cleared again by centrifugation and these
fractions were mixed with the initial supernatant fractions. For the
association studies between ATXN2 and FOX-2, HeLa cells were
washed with PBS, treated with lysis buffer [20 mM Tris-HCl
pH 7.4 (Merck; Darmstadt, Germany), 150 mM NaCl (Merck;
Darmstadt, Germany), 1 mM EDTA (Sigma; St. Louis, USA), 1%
Triton X-100 (Merck; Darmstadt, Germany), 1 ml/10 ml Benzo-
nase (Merck; Darmstadt, Germany), 1/25 complete Protease
Inhibitor Cocktail (Roche; Mannheim, Germany)], incubated for
30 minutes on ice, and lysates were cleared by centrifugation
(1 minute, 14000 rpm, RT).
For Co-IP experiments 1 mg of each cell lysate was incubated
with 4 ml antibody against FOX-2 [mouse anti-RBM9 M01
(Abnova; Taipei City, Taiwan)] or 2 ml rabbit anti-RBM9 (Bethyl
Laboratories; Montgomery, USA) and incubated overnight at
4uC. For ATXN1 overexpression experiments, 200 mg cell lysate
and 2 ml rabbit anti-RBM9 was incubated overnight at 4uCa s
well. Then, 30 ml Protein G-conjugated Dynabeads (Dynal-
Invitrogen; Paisly, UK) or 15–20 ml IgG-conjugated M-280
Dynabeads (Dynal-Invitrogen; Paisly, UK) were added to lysates
and further incubated for three hours. Dynabeads were pulled
down magnetically and washed twice in 3% BSA/PBS and twice
in PBS. Then, SDS-sample buffer was added to elute bound
proteins, and samples were incubated at 95uC for 10 minutes.
After separation of proteins by 10% SDS-PAGE and transfer to
a PVDF-membrane (Millipore; Billerica, USA) or nitrocellulose
membrane (Whatman; Springfield Mill, UK) using a PerfectBlue
semidry electroblotter (PeqLAB Biotechnologie; Erlangen, Ger-
many), membranes were incubated overnight with anti-ATXN1
[1:500, rabbit (Sigma; St. Louis, USA)], anti-ATXN2 [1:1000,
mouse (BD-Biosciences; Franklin Lakes, USA)] or anti-FLAGM2
[(1:1000, mouse (Sigma; St. Louis, USA)] as primary antibodies.
Following incubation with secondary antibodies [1:10000 POD-
conjugated anti-rabbit (Sigma; St. Louis, USA), 1:10000 POD-
conjugated anti-mouse (Sigma; St. Louis, USA)], proteins were
visualized using Western Lightning ECL (Perkin Elmer; Massa-
chusetts, USA).
RNAi experiments
HeLa and HEK293T cells were seeded in 12-well plates in
Dulbecco’s modified Eagle medium (Gibco-Invitrogen; Paisly,
UK) supplemented with 10% fetal bovine serum and incubated for
twenty-four hours. Then, 2.4 ml of the respective 20 mM siRNAs
[ON-TARGETplus SMARTpool, human RBM9 (FOX-2), ON-
TARGETplus Non Targeting Pool; (Dharmacon; Lafayette,
USA)] were mixed with 100 ml Dulbecco’s modified Eagle
medium and 3 ml Lipofectamine RNAiMAX Transfection Re-
agent (Invitrogen; Paisly, UK) for 20 minutes and subsequently
added to the cells. Total RNA was isolated from cells seventy-two
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Hilden, Germany) as recommended by the manufacturer.
Concentration of RNA isolates was determined with a Nano
Drop ND-1000 Spectrophotometer (NanoDrop Technologies;
Wilmington, USA).
Quantitative real-time PCR
The quantitative real-time PCR (RT-qPCR) was performed as
described [56]. Briefly, for reverse transcription, 2 mg of total
RNA was mixed with 0.5 ml Oligo-dT15-Primer (Promega;
Madison, USA), brought to a final volume of 9.5 ml, and kept
for 5 minutes at 70uC with a subsequent incubation for 5 minutes
at 4uC. Then, 9.4 ml DEPC (Diethylpyrocarbonate)-treated water
(Ambion; Austin, USA), 5 ml 5x M-MLV-reverse transcriptase
buffer (Promega; Madison, USA), 0.5 ml dNTPs and 0.1 mlM -
MLV reverse transcriptase (Promega; Madison, USA) were added,
samples were incubated for 1 hour at 42uC, and the reaction was
stopped by incubating samples at 65uC for 10 minutes. Then, RT-
qPCRs were performed in triplicates in a 10 ml volume and
processed with the ABI Prism 7900HT sequence detection system
(Applied Biosystems; Foster City, USA). Each reaction contained
50 ng cDNA, 0.25 mmol of the respective primers and 2.5 ml
SYBR Green PCR Master Mix (Applied Biosystems; Foster City,
USA). As reference genes ACTB (b-actin), HPRT (hypoxanthine
phosporibosyltransferase) and B2M (b-2-microglobulin) were used.
Fold change was calculated with the DDCt method (User Bulletin
#2, Applied Biosystems), and used for calculating the inclusion/
exclusion ratio of the analyzed mRNA transcripts. Standard error
of the mean was calculated for four independent experiments each
with three replicates. For detection of ATXN2 transcripts lacking
exon 18 conditions as described above were used, and samples
were loaded onto a 3% agarose gel. Primers used are listed in
Table 1.
Table 1: Oligonucleotides used in this study.
Oligonucleotides for PCR
sequence (59-39)
(underlined regions represent introduced restriction sites)
FOX-2-s-SalI GCGTCGACGATGGAGAAAAAGAAAATGGTA
FOX-2-as-NotI ATTTGCGGCCGCTTTATCAGTAGGGGGCAAATCGGC
FOX-2-nuc-as1-E12-E13-blunt CATATCCACCATAGAGGTCAGCACCGTAAA
FOX-2-nuc-s1-E12-E13-blunt TGACCTCTATGGTGGATATGCAGCCTACAG
FOX-2-nuc-as1-NotI ATTTGCGGCCGCTTTCAGTAGGGGGCAAATCGGC
ATXN1-NT-s-SalI ATGTCGACAAAATCCAACCAAGAG
ATXN1-NT-as-NotI TTAGCGGCCGCATCATTTCATGAAGTAGGG
ATXN1-AXH-s-SalI ATGTCGACGTCCGTGGCCTCCCCG
ATXN1-AXH-as-NotI TTAGCGGCCGCATCACACGGGCTGGCCCTTTTT
ATXN1-CT-s-SalI ATGTCGACGAGCGAGAACTTCAAC
ATXN1-CT-as-NotI TTAGCGGCCGCACTACTTGCCTACATT
TIAR-s-SalI GCGTCGACGATGATGGAAGACGACG
TIAR-as-NotI ATTTGCGGCCGCTCACTGTGTTTGGTAACT
Oligonucleotides for qPCR sequence (59-39)
ATXN1-E8-fw AGCCATAGCCCGGGCGTGGCCGTGA
ATXN1-E9-rev CTGGCTGGTTCTCTCCGGAC
ATXN2-E17-18-fw AGGCGTGCAACCTTTATACC
ATXN2-E18-rev CTGCTCTATATGTCTTGGCT
ATXN2-E17-19-fw AGGCGTGCAATACCAAATAT
ATXN2-E19-rev CTGAGACTGATAATGTGGCA
beta-actin_fw CGGATGTCCACGTCACACTT
beta-actin_rev GTTGCTATCCAGGCTGTGCT
B2M_fw ACTGAATTCACCCCCACTGA
B2M_rev CCTCCATGATGCTGCTTACA
HPRT_fw AGGAAAGCAAAGTCTGCATTGTT
HPRT_rev GGTGGAGATGATCTCTCAACTTTAA
MAP3K7-fw GGAGCAGTGTGGAGAGCTTG
MAP3K7-E12-rev CTGATATGACGATCTCAGGG
MAP3K7-E11-13-rev TGTCCGTTGCCTGTGGTTGC
FOX-2-fw CCTGGCTTCCCTTACCCTAC
FOX-2-rev AGCAGGCTGTGCATATCTGT
doi:10.1371/journal.pone.0037985.t001
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For localization studies of endogenous FOX-2 levels, HeLa and
HEK293T cells were cultivated and fixed as described above. For
overexpression experiments, cells were transfected with corre-
sponding constructs, incubated for forty-eight hours, treated with
cold methanol (Merck; Darmstadt, Germany) for 1 hour at –20uC,
washed with PBS and treated for 30 minutes with 3% BSA/PBS.
Then, cells were incubated with primary antibodies [1:200 mouse
anti-ATXN2 (BD-Biosciences; Franklin Lakes, USA); 1:200 rabbit
anti-ATXN2 (Sigma-Aldrich; St. Louis, USA), 1:200 rabbit anti-
RBM9 (Bethyl Laboratories; Montgomery, USA); 1:200 mouse
anti-RBM9 (Abnova; Taipei City, Taiwan); 1:500 mouse anti-
FLAGM2 (Sigma; St. Louis, USA); 1:500 mouse anti-HA (Roche;
Roche; Mannheim, Germany); 1:500 rabbit anti-MYC (Sigma; St.
Louis, USA); 1:500 mouse anti-MYC (Millipore; Billerica, USA)]
for one hour at RT or overnight at 4uC. Afterwards, cells were
washed three times with PBS and the respective dye-conjugated
secondary antibodies [1:500 anti-mouse Alexa Fluor488 (Molec-
ular Probes-Invitrogen; Paisly, UK); 1:500 anti-rabbit Alexa
Fluor568 (Molecular Probes-Invitrogen; Paisly, UK); 1:500 anti-
mouse-Cy3 (Jackson Immuno Research; West Grove, USA); 1:10
HA-Fluorescine (Roche; Mannheim, Germany)] were added for
one hour. Nuclei were stained with bisBenzimide [Hoechst
(Sigma; St. Louis, USA)] and cells were subsequently washed
with PBS and mounted with Fluoromount-G (Southern Biotech;
Birmingham, USA). Cells were analyzed using a confocal laser-
scanning microscope system LSM700 Imager M2 (Carl Zeiss;
Jena, Germany) with oil objectives (Zeiss Plan-NEOLUAR 40x/
1.3 or 63x/ 1.4 DIC). 8-bit images were taken and processed using
ZEN 2009 V5.5 software (Carl Zeiss; Jena, Germany).
Supporting Information
Figure S1 FOX-2 splice variants. (A) (Upper panel)
Schematic view of the FOX-2 splice variants FOX-2V1 and
FOX-2cyt. Sequence of the additional exon within FOX-2cyt is
indicated. (Lower panel) Alignment of the C-terminal region of
FOX-2V1 and FOX-2cyt. Insertion of an additional exon
(ENSE00001553845) causes a frame-shift resulting in a different
C-terminal ending. Yellow highlights identical amino acids. (B)
Localization of FOX-2V1 and FOX-2cyt. HeLa cells were
transiently transfected with expression plasmids pCMV-HA-
FOX-2V1 or pCMV-MYC-FOX-2cyt and incubated for twenty-
four hours. Afterwards, cells were fixed and proteins were stained
with HA-Fluorescine (upper panel) or anti-MYC antibody (lower
panel). Bars represent 20 mm.
(TIF)
Figure S2 FOX-2 accumulates in nuclear ATXN1 inclu-
sions in HEK293T cells. HEK293T cells expressing normal
and mutant ATXN1 were fixed forty-eight hours post transfection.
Endogenous level of FOX-2 was visualized using a specific
antibody (Abnova). Nuclei were stained using Hoechst. Bars
represent 20 mm.
(TIF)
Figure S3 FOX-2 localizes to stress granules under
stress conditions. (A) HeLa cells were transiently transfected
with plasmids pCMV-HA-FOX-2V1 or pCMV-MYC-FOX-2cyt.
Twenty-four hours post transfection, cells were left untreated
(upper panel) or exposed to 0.5 mM arsenite for one hour (lower
panel). Then, proteins FOX-2V1 and FOX-2cyt were visualized
with HA-Fluorescine or with an anti-MYC antibody as indicated
in Material and Methods. ATXN2 as stress granule marker
protein was co-stained using an anti-ATXN2 antibody (Sigma). (B)
For studying endogenous FOX-2 localization, HeLa cells left
untreated (upper panel) or exposed to 0.5 mM arsenite for one
hour (middle and lower panel) were fixed and stained with
antibodies against FOX-2 (Bethyl), ATXN2 (BD-Biosciences) or
TIAR. Nuclei were stained using Hoechst. Bars represent 20 mm.
(TIF)
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